van Geloven Thomas Pg, de Witte Pieter Bas, Laitinen Minna K, Campanacci Domenico A, Döring Kevin, Dammerer Dietmar, Mesregah Mohamed K, Appelman-Dijkstra Natasja M, Haara Mikko, Beltrami Giovanni, Hobusch Gerhard M, Kraus Tanja, Farr Sebastian, Soto-Montoya Camilo, Medellin Rincon Manuel R, Saeed Javeria, Funovics Phillipp T, van der Heijden Lizz, van de Sande Michiel Aj
Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Pediatric Orthopaedics, Erasmus MC Sophia Children Hospital, Rotterdam, The Netherlands.
J Child Orthop. 2025 Jul 24:18632521251355884. doi: 10.1177/18632521251355884.
Monostotic fibrous dysplasia is a rare benign fibro-osseous disorder. Proximal femoral monostotic fibrous dysplasia is especially vulnerable to pathological fracture and deformation, requiring specific treatment strategies. Literature on pediatric proximal femoral monostotic fibrous dysplasias is sparse and without consensus. We present the largest observational cohort study on various treatment methods of pediatric proximal femoral monostotic fibrous dysplasia.
Pediatric patients with proximal femoral monostotic fibrous dysplasia were included, from 10 academic hospitals for oncological orthopedics (2000-2021). Baseline characteristics, treatment strategies, and complications were assessed. Primary outcomes were failure rates, failure-free survival, and risk factors for failure. Failure was defined as fracture, progressive deformity, or surgical (re-)intervention after the start of treatment.
Forty-one pediatric patients with proximal femoral monostotic fibrous dysplasia were included (median age = 11 years (range = 6-16), = 21 (51%) male). Median follow-up was 5.1 years (range = 0.8-18.6). Index procedure was watchful waiting ( = 9), percutaneous procedure ( = 4), open procedure ( = 15), or internal fixation ( = 13). Failure rates were 11%, 50%, 40%, and 31%, respectively ( = 0.41). Overall, 2- and 5-year failure-free survival was stable at 87.5% (95% confidence interval = 64.6-110.4). Risk factors associated with failure were fracture at diagnosis (hazard ratio = 3.7, 95% confidence interval = 1.2-11.5), calcar involvement (hazard ratio = 2.6, 95% confidence interval = 0.7-9.4), and male sex (hazard ratio = 2.1, 95% confidence interval = 0.6-7.8).
In cases with low fracture and deformity risk, watchful waiting can be a viable management option for proximal femoral monostotic fibrous dysplasia. When intervention is necessary, internal fixation is advised to prevent fractures and deformity. Curettage with grafting or bone substitute injections should be used with hesitance. Currently, there is no clearly superior treatment for pediatric proximal femoral monostotic fibrous dysplasia, leaving treatment choices to be based on individual characteristics.
单骨型纤维结构不良是一种罕见的良性纤维-骨疾病。股骨近端单骨型纤维结构不良尤其易发生病理性骨折和畸形,需要特定的治疗策略。关于儿童股骨近端单骨型纤维结构不良的文献稀少且尚无共识。我们开展了关于儿童股骨近端单骨型纤维结构不良各种治疗方法的最大规模观察性队列研究。
纳入来自10家肿瘤骨科专科医院(2000 - 2021年)的股骨近端单骨型纤维结构不良患儿。评估基线特征、治疗策略及并发症。主要结局指标为失败率、无失败生存期及失败的危险因素。失败定义为治疗开始后发生骨折、进行性畸形或手术(再次)干预。
纳入41例股骨近端单骨型纤维结构不良患儿(中位年龄 = 11岁(范围 = 6 - 16岁),21例(51%)为男性)。中位随访时间为5.1年(范围 = 0.8 - 18.6年)。初次手术方式为观察等待(9例)、经皮手术(4例)、开放手术(15例)或内固定(13例)。失败率分别为11%、50%、40%和31%(P = 0.41)。总体而言,2年和5年无失败生存率稳定在87.5%(95%置信区间 = 64.6 - 110.4)。与失败相关的危险因素为诊断时骨折(风险比 = 3.7,95%置信区间 = 1.2 - 11.5)、股骨距受累(风险比 = 2.6,95%置信区间 = 0.7 - 9.4)及男性(风险比 = 2.1,95%置信区间 = 0.6 - 7.8)。
对于骨折和畸形风险较低的病例,观察等待可作为股骨近端单骨型纤维结构不良的一种可行治疗选择。如有必要进行干预,建议采用内固定以预防骨折和畸形。刮除植骨或骨替代物注射应谨慎使用。目前,对于儿童股骨近端单骨型纤维结构不良尚无明显更优的治疗方法,治疗选择应基于个体特征。